[Form 4] FIBROGEN INC Insider Trading Activity

Rhea-AI Filing Summary

FibroGen, Inc. (FGEN) reported insider buying by its Chief Executive Officer and Director in a Form 4 filing. On 11/13/2025, the reporting person purchased 1,000 shares of common stock at $9.18 per share. On 11/17/2025, an additional 2,700 shares were purchased at $9.0999 per share. After these transactions, the reporting person beneficially owned 24,939 shares of FibroGen common stock directly and 40 shares indirectly through a spouse. The filing was made by a single reporting person in the roles of both CEO and Director.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wettig Thane

(Last) (First) (Middle)

C/O FIBROGEN, INC.

350 BAY STREET, SUITE 100, #6009

(Street)

SAN FRANCISCO CA 94133

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FIBROGEN INC [ FGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/13/2025		P		1,000	A	$9.18	22,239	D
Common Stock	11/17/2025		P		2,700	A	$9.0999	24,939	D
Common Stock								40	I	By spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ John Alden, Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the latest Form 4 filing reveal about FibroGen (FGEN)?

The Form 4 shows that FibroGen's CEO and Director purchased 1,000 shares on 11/13/2025 at $9.18 and 2,700 shares on 11/17/2025 at $9.0999 per share.

How many FibroGen (FGEN) shares does the reporting person now beneficially own?

Following the reported transactions, the reporting person beneficially owns 24,939 shares of FibroGen common stock directly and 40 shares indirectly through a spouse.

What is the role of the reporting person in FibroGen (FGEN)?

The reporting person is both a Director and an Officer of FibroGen, serving as CEO.

On what dates did the insider stock purchases for FibroGen (FGEN) occur?

The insider purchases of FibroGen common stock occurred on 11/13/2025 and 11/17/2025, as reported in the Form 4.

Were the reported FibroGen (FGEN) transactions direct or indirect holdings?

The purchases reported in the Form 4 are held directly, while an additional 40 shares are reported as held indirectly by the spouse.

Is the FibroGen (FGEN) Form 4 filed by one or multiple reporting persons?

The Form 4 is indicated as being filed by one reporting person, not a group.